What was Sanjivani Paranteral's revenue in Q3 FY26?

Sanjivani Paranteral reported revenue of ₹22 Cr in Q3 FY26, a +27.1% change year-over-year.

Did Sanjivani Paranteral management deliver on previous promises?

Scorecard data is being built as historical quarters are processed.

SANJIVANIPARANTERAL Diversified 10 Feb 2026

Sanjivani Paranteral Ltd — Q3 FY26

Q: What guidance did Sanjivani Paranteral management give?

FY27 standalone revenue target of ₹90 crore: Management expects base business (standalone) to reach ₹90 crore in FY27, implying ~20% growth over FY26 estimated ₹73-75 crore.

Sanjivani Paranteral delivered a strong Q3 FY26 with consolidated revenue of ₹22.1 crore (+27.1% YoY) and EBITDA margin expansion of 230 bps to 18.5%, driven by favorable product mix and first-time contribution from the Pune IV fluids JV (₹1.2 crore).

Revenue ₹22 Cr +27.1%

EBITDA ₹4 Cr +44.8%

PAT ₹3 Cr +46.3%

EBITDA Margin 18.5% +230bps

Duration 33 min

Read Time 1 min read

✓ Verified against BSE filing

2-Minute Summary

✦ AI-Generated from Full Transcript

Sanjivani Paranteral delivered a strong Q3 FY26 with consolidated revenue of ₹22.1 crore (+27.1% YoY) and EBITDA margin expansion of 230 bps to 18.5%, driven by favorable product mix and first-time contribution from the Pune IV fluids JV (₹1.2 crore). Standalone revenue grew 20.2% to ₹20.9 crore, with oral solids surging 153% YoY. Management guided FY27 standalone revenue of ₹90 crore and SPL Infusion revenue of ₹60-65 crore, implying ~50% consolidated growth. The Pune facility is ramping up (23-27% utilization) and targets 40-50% utilization by FY27. Risks include execution delays in product approvals and potential margin volatility from product mix shifts.

Risks4 trackedTranscriptfull text

Research workspace

Focused Modules

!Risks 4 risks

Risk Intelligence

Execution risk in product approvals for Pune facility

View Risks →

≡Transcript Full text

Call Transcript

Full transcript text is available on this route.

Read Transcript →

Quarter Snapshot

Injectable Revenue ₹11.7 crore

-9.7% YoY

Injectable segment declined due to product mix shift; oral solids grew 153%.

Oral Solids Revenue ₹8.6 crore

+153.3% YoY

Strong growth driven by export demand and product mix improvements.

SPL Infusion Revenue ₹1.2 crore

First-time contribution

Pune IV fluids JV began commercial production; initial ramp-up phase.

Export Share 76.9%

N/A

Exports to Middle East, Africa, Latin America remain dominant revenue source.

Fast read

Guidance and risk preview

Top guidance FY27 standalone revenue target of ₹90 crore

Management expects base business (standalone) to reach ₹90 crore in FY27, implying ~20% growth over FY26 estimated ₹73-75 crore.

Top risk Execution risk in product approvals for Pune facility

Ramp-up of SPL Infusion depends on obtaining approvals for 23-24 products; delays could impact revenue targets.

View Risks →